GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » Debt-to-Revenue

Guizhounli Pharmaceutical Co (SHSE:603439) Debt-to-Revenue : 0.45 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Guizhounli Pharmaceutical Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Guizhounli Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥532 Mil. Guizhounli Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥210 Mil. Guizhounli Pharmaceutical Co's annualized Revenue for the quarter that ended in Mar. 2025 was ¥1,634 Mil. Guizhounli Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.45.


Guizhounli Pharmaceutical Co Debt-to-Revenue Historical Data

The historical data trend for Guizhounli Pharmaceutical Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhounli Pharmaceutical Co Debt-to-Revenue Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.21 0.17 0.34 0.28

Guizhounli Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.30 0.27 0.22 0.45

Competitive Comparison of Guizhounli Pharmaceutical Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Guizhounli Pharmaceutical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guizhounli Pharmaceutical Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guizhounli Pharmaceutical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Guizhounli Pharmaceutical Co's Debt-to-Revenue falls into.


;
;

Guizhounli Pharmaceutical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Guizhounli Pharmaceutical Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(397.17 + 209.512) / 2144.386
=0.28

Guizhounli Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(531.831 + 209.7) / 1634.356
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.


Guizhounli Pharmaceutical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Guizhounli Pharmaceutical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Guizhounli Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
Executives
Zhang Hai Director
Wang Jue Ben senior management
Zhang Hong Yu Directors, senior managers
Wang Yi senior management
Zhang Qian Fan Directors, senior managers
Sheng Yong Jian Director

Guizhounli Pharmaceutical Co Headlines

No Headlines